- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00047580
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
December 10, 2015 updated by: Elan Pharmaceuticals
A Multicenter, Open-Label, Randomized, 4-Way Crossover Trial of the Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex (Tizanidine Hydrochloride) Tablets Taken Under Fed and Fasted Conditions in Patients With Moderate to Severe Spasticity
This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted state (before a meal) in patients with moderate to severe spasticity.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment
120
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85710
- Radiant Research
-
-
California
-
Encinitas, California, United States, 92024
- The Neurology Center
-
Northridge, California, United States, 91325
- Northridge Neurological Center
-
Oceanside, California, United States, 92056
- The Neurology Center
-
Walnut Creek, California, United States, 94598
- Neurology Medical Group of Diablo Valley
-
-
Colorado
-
Englewood, Colorado, United States, 80110
- Colorado Neurology Movement Disorders Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale Center for MS Treatment and Research
-
-
Florida
-
Plantation, Florida, United States, 33324
- Neurology Clinic Research Institution
-
Tampa, Florida, United States, 33609
- Axiom Clinical Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- NeuroTrials Research, Inc.
-
Atlanta, Georgia, United States, 30338
- Comprehensive Neurology Specialists, PC
-
-
Illinois
-
Springfield, Illinois, United States, 62702
- Springfield Clinic Neuroscience Institute
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55422
- The Minneapolis Clinic of Neurology, Ltd.
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136-8327
- Neurological Associates of Tulsa, Inc.
-
-
Oregon
-
Medford, Oregon, United States, 97504-8456
- Medford Neurological and Spine Clinic
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02818
- Sargent Rehabilitation Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- IRB approved ICF must be signed and dated by patient or patient's legal representative
- Male or Female 18 years of age or older
- Clinical diagnosis of established spasticity (at least 3 months) secondary to multiple sclerosis, stroke, or spinal cord injury
- Currently on stable dose of up to 36mg of Zanaflex
- Must be able to swallow tablets or capsules whole
Exclusion Criteria:
- Patients with dementia, aphasia, or other deficits in cognition
- Unwilling or unable to complete cognition test or daily diary
- Known sensitivity to Zanaflex
- Taking Zanaflex on an as needed ("prn") basis
- Currently being treated with drugs having significant effects at the alpha2 receptors whether agonist (i.e., clonidine, methyldopa) or antagonist (i.e., phenothiazines, imipramine)
- Currently on any other muscle relaxant or any drugs having muscle relaxant properties (including baclofen, dantrolene, diazepam and other benzodiazepines, tranquilizers, narcotic analgesics, high dose neuroleptics, chlormezanone, meprobamate, methocarbamol, orphenadrine, carisoprodol, gabapentin and clonidine
- Taking any over-the-counter or prescription sleep aids within 30 days prior to screening
- Use of illegal drugs or legal drugs for recreational purposes or excessive use of alcohol
- Patients suffering from disabling, symptomatic hypotension (i.e., syncope)
- Patients having any systemic disease such as renal insufficiency, clinically relevant elevations in hepatic transaminase, severe, uncontrolled systemic hypertension
- Any clinically significant illnesses, within four weeks of screening
- Patients with known sleep disorders
- Patients who participated in a clinical trial within thiry days prior to screening
- Women of childbearing potential who are pregnant, have a positive serum pregnancy test, lactating, or do not or will not take adequate contraceptive precautions for the duration of trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2002
Study Completion
September 1, 2002
Study Registration Dates
First Submitted
October 8, 2002
First Submitted That Met QC Criteria
October 9, 2002
First Posted (Estimate)
October 10, 2002
Study Record Updates
Last Update Posted (Estimate)
December 14, 2015
Last Update Submitted That Met QC Criteria
December 10, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neurologic Manifestations
- Wounds and Injuries
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Trauma, Nervous System
- Spinal Cord Diseases
- Muscle Hypertonia
- Multiple Sclerosis
- Sclerosis
- Spinal Cord Injuries
- Muscle Spasticity
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Anticonvulsants
- Neuromuscular Agents
- Muscle Relaxants, Central
- Tizanidine
Other Study ID Numbers
- ELN021-502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on tizanidine hydrochloride capsule
-
Second Affiliated Hospital, School of Medicine,...SICHUAN CREDIT PHARMACEUTICAL CO., LTD.Not yet recruitingMigraine Without Aura | Migraine With AuraChina
-
ViiV HealthcareCompletedHIV InfectionsUnited Kingdom
-
Peking Union Medical College HospitalNot yet recruitingLocally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid CarcinomaChina
-
Betta Pharmaceuticals Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer | EGFR Gene MutationChina
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer... and other collaboratorsWithdrawnChemotherapy-related DiarrheaChina
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Daiichi Sankyo, Inc.CompletedTenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Giant Cell Tumors of the Tendon SheathUnited States, France, Australia, Denmark, Spain, Netherlands, Germany, Canada, United Kingdom, Hungary, Italy, Poland
-
Lyndra Inc.TerminatedHealthy | Gastric RetentionUnited Kingdom
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMedullary Thyroid CancerChina